Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: STEAMROLLER who wrote (31622)	12/21/1998 8:08:00 AM
From: RockyBalboa	Read Replies (1) \| Respond to of 119973

The life expectation of BAAT traders seems to be measured in weeks if not days. Only that the outcome is deterministic in the very contradiction of the results of trading internet companies. How high is the average % payout of Las Vegas slot machines? C.

To: STEAMROLLER who wrote (31622)	12/21/1998 8:21:00 AM
From: Deeber	Respond to of 119973

IMNR news: Monday December 21, 7:00 am Eastern Time Company Press Release SOURCE: Immune Response Corporation IMNR Announces Results From Phase IIb Clinical Trial for Rheumatoid Arthritis CARLSBAD, Calif., Dec. 21 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) reported today results from the company's recently completed Phase IIb clinical trial for the treatment of Rheumatoid Arthritis (RA). This five-arm, double-blind, placebo-controlled clinical trial in 340 patients was designed to evaluate the company's potential T-cell receptor (TCR) peptide therapeutic vaccine in an effort to select the best dose and formulation for future clinical development. The company believes that the results suggest a favorable treatment effect according to the American College of Rheumatology criteria for improvement (ACR 20 criteria) with statistical significance at one time point after the third injection, and was consistent with and expanded upon the results shown in the previous phase II trial. The results also suggest that the treatments were safe and well tolerated. Although the treatment effect was not maintained throughout the trial in the entire patient population, when patients receiving more than physiological doses (>7.5 mg/day) of prednisone (a corticosteroid used to suppress inflammation) were excluded, the remainder of the patients appear to have had a greater treatment effect at the end of the trial. The company believes that in addition to suppressing inflammation, the corticosteroid treatment received by this subset of patients may also prevent the stimulation of the immune system by the TCR peptide therapeutic vaccine. In addition, early stage patients (<2 years of disease), were those that appeared to respond best to the therapy. Taken together, these results may support the Company's belief that the TCR peptide therapeutic vaccine is a useful approach for the treatment of rheumatoid arthritis. The company intends to continue discussions in an effort to select a corporate partner to further develop this product. The Immune Response Corporation, a biopharmaceutical company based in Carlsbad, California, develops immune-based therapies to induce specific T cell responses for the treatment of HIV, autoimmune diseases and cancer. The Company is conducting clinical trials on immune-based therapies for HIV, rheumatoid arthritis, psoriasis, multiple sclerosis, colon cancer and brain cancer, and preclinical studies for melanoma and prostate cancers. In addition, the Company is developing a delivery technology to enable intravenously-injected genes to target the liver. This gene therapy program includes preclinical studies for the treatment of hemophilia and hepatitis. This news release contains forward-looking statements. Actual results may vary materially from those expected due to a variety of risk factors, including whether these results will be predictive of clinical benefit, the uncertainty of successful completion of clinical trials, and those risks set forth from time to time in the Immune Response Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 1997. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. SOURCE: Immune Response Corporation